Overview

Efficacy of Lu 31-130 in Patients With Schizophrenia

Status:
Completed
Trial end date:
2009-11-01
Target enrollment:
Participant gender:
Summary
The main purpose with the study is to explore the efficacy and safety of Lu 31-130 in patients suffering from schizophrenia compared to a standard antipsychotic drug.
Phase:
Phase 2
Details
Lead Sponsor:
H. Lundbeck A/S
Treatments:
Olanzapine